Business
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting TherapyALLO-316 Data Also Highlight the Potential of Dagger™ Technology, a Next Generation Allogeneic Platform Designed to Control Immune Rejection of AlloCAR T Cells SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will present interim data from its Phase 1 TRAVERSE trial of ALLO-316, the Company’s first AlloCAR T candidate for solid tumors, in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place in April in Orlando, Florida. The AACR conference presentation follows the release of preliminary ALLO-316 data reported at the Company’s R&D Showcase event in November 2022. “We are excited to present ALLO-316 data for the first time at a medical conference,” said Zachary Roberts, M.D., Ph.D., Executive Vice President of Research & Development. “There is an urgent need for innovation for patients with renal cell carcinoma who have failed immune checkpoint inhibitors and targeted therapy. Initial data from this trial shared at our R&D Showcase in November 2022 demonstrated the potential of ALLO-316 in patients with CD70 expressing advanced or metastatic RCC, and we look forward to further exploring the potential of this AlloCAR T product candidate in RCC and potentially other CD70-expressing tumors.” Dagger™ technology is a proprietary platform designed to control rejection of AlloCAR T cells by the host immune cells and is an intrinsic property of ALLO-316. The results from this trial indicate that ALLO-316 possesses antitumor activity as well as the anti-rejection effect. “The Dagger technology has been shown preclinically to counter premature rejection of AlloCAR T cells via the elimination of CD70 positive, alloreactive host T cells,” said Barbra Sasu, Ph.D., Chief Scientific Officer of Allogene. “The demonstration of this novel mechanism of action in the clinic opens the possibility of combining the CD70 Dagger receptor with other anti-tumor CARs to create dual-targeting, rejection-resistant next gen...